BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

142 related articles for article (PubMed ID: 28923666)

  • 1. Validation of a Molecular Risk Score for Prognosis of Patients With Acute Promyelocytic Leukemia Treated With All-trans Retinoic Acid and Chemotherapy-containing Regimens.
    Hecht A; Doll S; Altmann H; Nowak D; Lengfelder E; Röllig C; Ehninger G; Spiekermann K; Hiddemann W; Weiß C; Hofmann WK; Nolte F; Platzbecker U
    Clin Lymphoma Myeloma Leuk; 2017 Dec; 17(12):889-896.e5. PubMed ID: 28923666
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Mutations of Epigenetic Modifier Genes as a Poor Prognostic Factor in Acute Promyelocytic Leukemia Under Treatment With All-Trans Retinoic Acid and Arsenic Trioxide.
    Shen Y; Fu YK; Zhu YM; Lou YJ; Gu ZH; Shi JY; Chen B; Chen C; Zhu HH; Hu J; Zhao WL; Mi JQ; Chen L; Zhu HM; Shen ZX; Jin J; Wang ZY; Li JM; Chen Z; Chen SJ
    EBioMedicine; 2015 Jun; 2(6):563-71. PubMed ID: 26285909
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Internal tandem duplication of the FLT3 gene confers poor overall survival in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based chemotherapy: an International Consortium on Acute Promyelocytic Leukemia study.
    Lucena-Araujo AR; Kim HT; Jacomo RH; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Chauffaille Mde L; Chiattone CS; Lima AS; Ruiz-Argüelles G; Undurraga MS; Martinez L; Kwaan HC; Gallagher R; Niemeyer CM; Schrier SL; Tallman MS; Grimwade D; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Sanz MA; Rego EM
    Ann Hematol; 2014 Dec; 93(12):2001-10. PubMed ID: 24981688
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining gene mutation with gene expression analysis improves outcome prediction in acute promyelocytic leukemia.
    Lucena-Araujo AR; Coelho-Silva JL; Pereira-Martins DA; Silveira DR; Koury LC; Melo RAM; Bittencourt R; Pagnano K; Pasquini R; Nunes EC; Fagundes EM; Gloria AB; Kerbauy F; de Lourdes Chauffaille M; Bendit I; Rocha V; Keating A; Tallman MS; Ribeiro RC; Dillon R; Ganser A; Löwenberg B; Valk PJM; Lo-Coco F; Sanz MA; Berliner N; Rego EM
    Blood; 2019 Sep; 134(12):951-959. PubMed ID: 31292112
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Prognostic importance of expression of the Wilms' tumor 1 gene in newly diagnosed acute promyelocytic leukemia.
    Hecht A; Nolte F; Nowak D; Nowak V; Reinwald M; Hanfstein B; Faldum A; Büchner T; Spiekermann K; Sauerland C; Weiss C; Hofmann WK; Lengfelder E
    Leuk Lymphoma; 2015; 56(8):2289-95. PubMed ID: 25426668
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High expression of the Ets-related gene (ERG) is an independent prognostic marker for relapse-free survival in patients with acute promyelocytic leukemia.
    Hecht A; Nowak D; Nowak V; Hanfstein B; Faldum A; Büchner T; Spiekermann K; Sauerland C; Lengfelder E; Hofmann WK; Nolte F
    Ann Hematol; 2013 Apr; 92(4):443-9. PubMed ID: 23250622
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Clinical impact of galectin-3 in newly diagnosed t (15;17)(q22;q21)/PML-RARa acute promyelocytic leukemia treated with all-trans retinoic acid and arsenic trioxide-based regimens.
    Gao N; Wang XX; Sun JR; Yu WZ; Li XZ
    Ann Hematol; 2017 May; 96(5):711-718. PubMed ID: 28238096
    [TBL] [Abstract][Full Text] [Related]  

  • 8. High WT1 expression is an early predictor for relapse in patients with acute promyelocytic leukemia in first remission with negative PML-RARa after anthracycline-based chemotherapy: a single-center cohort study.
    Yoon JH; Kim HJ; Kwak DH; Park SS; Jeon YW; Lee SE; Cho BS; Eom KS; Kim YJ; Lee S; Min CK; Cho SG; Kim DW; Lee JW; Min WS
    J Hematol Oncol; 2017 Jan; 10(1):30. PubMed ID: 28114959
    [TBL] [Abstract][Full Text] [Related]  

  • 9. All-trans retinoic acid with daunorubicin or idarubicin for risk-adapted treatment of acute promyelocytic leukaemia: a matched-pair analysis of the PETHEMA LPA-2005 and IC-APL studies.
    Sanz MA; Montesinos P; Kim HT; Ruiz-Argüelles GJ; Undurraga MS; Uriarte MR; Martínez L; Jacomo RH; Gutiérrez-Aguirre H; Melo RA; Bittencourt R; Pasquini R; Pagnano K; Fagundes EM; Vellenga E; Holowiecka A; González-Huerta AJ; Fernández P; De la Serna J; Brunet S; De Lisa E; González-Campos J; Ribera JM; Krsnik I; Ganser A; Berliner N; Ribeiro RC; Lo-Coco F; Löwenberg B; Rego EM;
    Ann Hematol; 2015 Aug; 94(8):1347-56. PubMed ID: 25975975
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Expression of CD56 is an unfavorable prognostic factor for acute promyelocytic leukemia with higher initial white blood cell counts.
    Ono T; Takeshita A; Kishimoto Y; Kiyoi H; Okada M; Yamauchi T; Emi N; Horikawa K; Matsuda M; Shinagawa K; Monma F; Ohtake S; Nakaseko C; Takahashi M; Kimura Y; Iwanaga M; Asou N; Naoe T;
    Cancer Sci; 2014 Jan; 105(1):97-104. PubMed ID: 24206578
    [TBL] [Abstract][Full Text] [Related]  

  • 11. An analysis of the impact of CD56 expression in de novo acute promyelocytic leukemia patients treated with upfront all-trans retinoic acid and anthracycline-based regimens.
    Sobas M; Montesinos P; Boluda B; Bernal T; Vellenga E; Nomdedeu J; González-Campos J; Chillón M; Holowiecka A; Esteve J; Bergua J; González-Sanmiguel JD; Gil-Cortes C; Tormo M; Salamero O; Manso F; Fernández I; de la Serna J; Moreno MJ; Pérez-Encinas M; Krsnik I; Ribera JM; Escoda L; Lowenberg B; Sanz MA;
    Leuk Lymphoma; 2019 Apr; 60(4):1030-1035. PubMed ID: 30322324
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Clinical characteristics and outcome of childhood acute promyelocitic leukemia (APL) in Saudi Arabia: a multicenter SAPHOS leukemia group study.
    Jastaniah W; Alsultan A; Al Daama S; Ballourah W; Bayoumy M; Al-Anzi F; Al Shareef O; Abrar MB; Al Sudairy R; Al Ghemlas I
    Hematology; 2018 Jul; 23(6):316-323. PubMed ID: 29212418
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Effect of all-trans retinoic acid on the newly diagnosed acute promyelocytic leukaemia: our experience].
    Rolovitsh Z; Cholovitsh M; Elezovitsh I; Vidovitsh A; Radoshevitsh-Radojkovitsh N; Boshkovitsh D; Novak A; Basara N
    Srp Arh Celok Lek; 1995; 123(11-12):279-85. PubMed ID: 16296239
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Clinical significance of CD56 expression in patients with acute promyelocytic leukemia treated with all-trans retinoic acid and anthracycline-based regimens.
    Montesinos P; Rayón C; Vellenga E; Brunet S; González J; González M; Holowiecka A; Esteve J; Bergua J; González JD; Rivas C; Tormo M; Rubio V; Bueno J; Manso F; Milone G; de la Serna J; Pérez I; Pérez-Encinas M; Krsnik I; Ribera JM; Escoda L; Lowenberg B; Sanz MA; ;
    Blood; 2011 Feb; 117(6):1799-805. PubMed ID: 21148082
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Arsenic trioxide and all-trans retinoic acid treatment for acute promyelocytic leukaemia in all risk groups (AML17): results of a randomised, controlled, phase 3 trial.
    Burnett AK; Russell NH; Hills RK; Bowen D; Kell J; Knapper S; Morgan YG; Lok J; Grech A; Jones G; Khwaja A; Friis L; McMullin MF; Hunter A; Clark RE; Grimwade D;
    Lancet Oncol; 2015 Oct; 16(13):1295-305. PubMed ID: 26384238
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Characteristics and prognosis analysis of additional chromosome abnormalities in newly diagnosed acute promyelocytic leukemia treated with arsenic trioxide as the front-line therapy.
    Lou Y; Suo S; Tong H; Ye X; Wang Y; Chen Z; Qian W; Meng H; Mai W; Huang J; Tong Y; Jin J
    Leuk Res; 2013 Nov; 37(11):1451-6. PubMed ID: 23958062
    [TBL] [Abstract][Full Text] [Related]  

  • 17. CD56 expression is an indicator of poor clinical outcome in patients with acute promyelocytic leukemia treated with simultaneous all-trans-retinoic acid and chemotherapy.
    Ferrara F; Morabito F; Martino B; Specchia G; Liso V; Nobile F; Boccuni P; Di Noto R; Pane F; Annunziata M; Schiavone EM; De Simone M; Guglielmi C; Del Vecchio L; Lo Coco F
    J Clin Oncol; 2000 Mar; 18(6):1295-300. PubMed ID: 10715300
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Improved outcome of acute promyelocytic leukemia with high WBC counts over the last 15 years: the European APL Group experience.
    Kelaidi C; Chevret S; De Botton S; Raffoux E; Guerci A; Thomas X; Pigneux A; Lamy T; Rigal-Huguet F; Meyer-Monard S; Chevallier P; Maloisel F; Deconinck E; Ferrant A; Fegueux N; Ifrah N; Sanz M; Dombret H; Fenaux P; Adès L
    J Clin Oncol; 2009 Jun; 27(16):2668-76. PubMed ID: 19414681
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The influence of Wilms' tumor 1 gene expression level on prognosis and risk stratification of acute promyelocytic leukemia patients.
    Mitrovic M; Kostic T; Virijevic M; Karan-Djurasevic T; Suvajdzic Vukovic N; Pavlovic S; Tosic N
    Int J Lab Hematol; 2020 Feb; 42(1):82-87. PubMed ID: 31830382
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Sequential targeted therapy for relapsed acute promyelocytic leukemia with all-trans retinoic acid and anti-CD33 monoclonal antibody M195.
    Jurcic JG; Caron PC; Miller WH; Yao TJ; Maslak P; Finn RD; Larson SM; Warrell RP; Scheinberg DA
    Leukemia; 1995 Feb; 9(2):244-8. PubMed ID: 7869759
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.